Cost-effectiveness of licensed treatment options for restless legs syndrome in the UK and Sweden

Author： Lees M.   Roberts G.   Tabberer M.   DasGupta R.   Finnern H. W.    

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.24, Iss.10, 2008-10, pp. : 2919-2930

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome

By  

Integrative Medicine International, Vol. 1, Iss. 1, 2014-05 ,pp. : 32-43

Karger

Access to resources Recommend Favorite

The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden

By Zethraeus N.   Ström O.   Borgström F.   Kanis J.   Jönsson B.  

Osteoporosis International, Vol. 19, Iss. 6, 2008-06 ,pp. : 819-827

Springer Publishing Company

Access to resources Recommend Favorite

A cost-effectiveness analysis of subcutaneous interferon beta-1a 44mcg 3-times a week vs no treatment for patients with clinically isolated syndrome in Sweden

By Fredrikson Sten  

Journal of Medical Economics, Vol. 16, Iss. 6, 2013-06 ,pp. : 756-762

Informa Healthcare

Access to resources Recommend Favorite

The powerful pre‐treatment effect: placebo responses in restless legs syndrome trials

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 19, Iss. 10, 2012-10 ,pp. : 1305-1310

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost‐effectiveness implications of suboptimal treatment for different severities of Alzheimer's disease in the UK

By  

INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, Vol. 33, Iss. 2, 2018-02 ,pp. : 307-315

John Wiley & Sons Inc

Access to resources Recommend Favorite